{"name":"Bioverativ Therapeutics Inc.","slug":"bioverativ-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2022-01-01","label":"Enjaymo first approved","drug":"Enjaymo","drugSlug":"sutimlimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"FIX","genericName":"FIX","slug":"fix","indication":"Hemophilia B (Factor IX deficiency) — prevention and treatment of bleeding episodes","status":"marketed"},{"name":"FVIII (PK subgroup only)","genericName":"FVIII (PK subgroup only)","slug":"fviii-pk-subgroup-only","indication":"Hemophilia A (factor VIII deficiency) — prevention and treatment of bleeding episodes","status":"phase_3"},{"name":"Factor VIII (rFVIIIFc)","genericName":"Factor VIII (rFVIIIFc)","slug":"factor-viii-rfviiifc","indication":"Hemophilia A (treatment and prophylaxis of bleeding episodes)","status":"phase_3"},{"name":"BIIB031 (rFVIIIFc)","genericName":"BIIB031 (rFVIIIFc)","slug":"biib031-rfviiifc","indication":"Hemophilia A (treatment and prophylaxis of bleeding episodes)","status":"phase_3"},{"name":"Factor IX (rFIXFc)","genericName":"Factor IX (rFIXFc)","slug":"factor-ix-rfixfc","indication":"Hemophilia B (Factor IX deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes","status":"phase_3"},{"name":"rFVIIIFc","genericName":"rFVIIIFc","slug":"rfviiifc","indication":"Hemophilia A (congenital Factor VIII deficiency) for routine prophylaxis and on-demand treatment of bleeding episodes","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Enjaymo","genericName":"SUTIMLIMAB","slug":"sutimlimab","indication":"Cold autoimmune hemolytic anemia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Advate®","genericName":"Advate®","slug":"advate","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Enjaymo","genericName":"SUTIMLIMAB","slug":"sutimlimab","phase":"marketed","mechanism":"Enjaymo works by blocking the activity of the complement C1s subcomponent, a part of the immune system that can mistakenly attack red blood cells.","indications":["Cold autoimmune hemolytic anemia"],"catalyst":""},{"name":"FIX","genericName":"FIX","slug":"fix","phase":"marketed","mechanism":"FIX is a recombinant coagulation Factor IX that replaces deficient or dysfunctional Factor IX to restore the intrinsic coagulation pathway in patients with hemophilia B.","indications":["Hemophilia B (Factor IX deficiency) — prevention and treatment of bleeding episodes","Hemophilia B — perioperative management"],"catalyst":""},{"name":"FVIII (PK subgroup only)","genericName":"FVIII (PK subgroup only)","slug":"fviii-pk-subgroup-only","phase":"phase_3","mechanism":"FVIII is a recombinant coagulation factor VIII that replaces deficient or dysfunctional clotting factor to restore hemostasis in hemophilia A patients.","indications":["Hemophilia A (factor VIII deficiency) — prevention and treatment of bleeding episodes"],"catalyst":""},{"name":"Factor VIII (rFVIIIFc)","genericName":"Factor VIII (rFVIIIFc)","slug":"factor-viii-rfviiifc","phase":"phase_3","mechanism":"rFVIIIFc is a recombinant Factor VIII protein fused to the Fc domain of human immunoglobulin G, which replaces deficient clotting Factor VIII to restore hemostasis in hemophilia A patients.","indications":["Hemophilia A (treatment and prophylaxis of bleeding episodes)"],"catalyst":""},{"name":"Advate®","genericName":"Advate®","slug":"advate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIIB031 (rFVIIIFc)","genericName":"BIIB031 (rFVIIIFc)","slug":"biib031-rfviiifc","phase":"phase_3","mechanism":"rFVIIIFc is a recombinant Factor VIII fused to the Fc domain of human immunoglobulin G, which replaces deficient clotting Factor VIII to restore hemostatic function in hemophilia A.","indications":["Hemophilia A (treatment and prophylaxis of bleeding episodes)"],"catalyst":""},{"name":"Factor IX (rFIXFc)","genericName":"Factor IX (rFIXFc)","slug":"factor-ix-rfixfc","phase":"phase_3","mechanism":"Factor IX (rFIXFc) is a recombinant clotting factor IX fused to the Fc domain of human immunoglobulin G, which replaces deficient Factor IX to restore blood coagulation in hemophilia B patients.","indications":["Hemophilia B (Factor IX deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes"],"catalyst":""},{"name":"rFVIIIFc","genericName":"rFVIIIFc","slug":"rfviiifc","phase":"marketed","mechanism":"rFVIIIFc is a recombinant Factor VIII fused to the Fc domain of human immunoglobulin G, which replaces deficient clotting Factor VIII to restore hemostasis in hemophilia A patients.","indications":["Hemophilia A (congenital Factor VIII deficiency) for routine prophylaxis and on-demand treatment of bleeding episodes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"globenewswire.com","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - globenewswire.com","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZGFDeEtITEVMQXV0ZHczcEx1NW4ybWx5X1BLNE1ZaGM1YXZJcjhaVXQ0S0Q1OEhBNW9PVkRkbUlQV3VYeW9ybHlTWnBaN2dKMkVXNF9iUFdzUnphSEJCODZzc2ZzenAzazRTWDdvRWg5OW9jR0FUWDA1WU5VcWxvNEY0N1Z0MjB1RFdrNko2dUplVDhJMHgzRXRPbmtBSmQ0QVJJMTY2cFhMZFNGMno4M2t1WHllRzEtY3FVZU9qSjlvREdjVmJTaEFZRnVYQTVmRWk3Y3FMSVlxM2VQ?oc=5","date":"2026-03-04","type":"pipeline","source":"PR Newswire","summary":"Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - PR Newswire","headline":"Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQQkstR2VWVEJINkN1c200ZDhnbEJFczlOMFZ6Y2NqU19zaHZGQURBLUZjdjNsbUJ6YVVId3ZBX3VYYktHSmw0RERmdndhaG94S0dyVzV1bE5HUFM2Q2tPcU1iQWt5NU41RlNqMy1qcDNzX2hDOUxrbGNzbmNaTTVfb0FPSWZXY1c1bDBCSXdTYlFiX2kzb210R2FIb3JtcE1aaGNWSnoyTQ?oc=5","date":"2025-02-06","type":"pipeline","source":"BioWorld News","summary":"Low sales, safety concerns doom biopharma’s ROI for mega-M&As - BioWorld News","headline":"Low sales, safety concerns doom biopharma’s ROI for mega-M&As","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPR3M4Mk9VOExaM0J6QUFlbENJRHc5ZjZjcXQzdGhaNENWSlNIQU5YNUhESmYxNHlELVYxczlkM2hCQ0pURDZ0TnpMMVV6STZQeTdUbFktbndSTHdCU09OaDQ4cE1SVHB1VXN5YVYzU2F2VnpNdWdjTFVhNXBEOGxyakZBd1JSd21NcE0zeDNxOHA0TkpkMjN1Rmg4NXF1WU1TZUhPaVNyc2pieDRTbTZSWDA2RXpFdmNCRkctcGxkdUQ3WDZoRHc?oc=5","date":"2023-12-21","type":"pipeline","source":"pearceip.law","summary":"Erroneous understanding of Australian law not an error qualifying for an extension of time - pearceip.law","headline":"Erroneous understanding of Australian law not an error qualifying for an extension of time","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE44VmxkTVF2eWNiSV9oaHdZbkkwNTllanpzcjFGV3pFNTRRbTdOQnNnTFF0WnlNYndha0xXb2pkb0ZPSVE2MWtwZThCSlc5UkJFdE5VN1A4d1I3czFicHc?oc=5","date":"2019-11-05","type":"pipeline","source":"Nature","summary":"People - Nature","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOWnBsV0dGSk1PU1YwMUJoQ1dPR1llc1dTS2g3RWkzaXo0Q3pSYm9zcEt2VkliVmd2WUJZYTRwcXgzYXp0aWdfSHI0Qkwzcm0xXzhNVzQwSVc2YlFoWjEteW05WWRUY2lzMk04eVZFTEFJbjR6Y0hscFRucEFxUDJEMkN4RFFlUXY2Zl9FVVJGODlGVm5weVI0WHo2MU1WUU9VM1dzRC05N3VsV1VX?oc=5","date":"2019-10-02","type":"pipeline","source":"Fierce Biotech","summary":"Ex-Bioverativ CEO John Cox lands at T-cell biotech Torque Therapeutics - Fierce Biotech","headline":"Ex-Bioverativ CEO John Cox lands at T-cell biotech Torque Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPTjFMYkdxX2NrSEtUa2JjS3JLb0t0WmlNQTRlaVhzX0lLTnZJNW0yeWhoY3ZvTnBlblNwLVBzanRfNUlBWGVIUUtfcEE3VlJjVmFaY2hTZU93MktaazhPZ2lIQkdyNV9lYmZRMFpMLUlWOUNwMVg4M180RFpsZWZRcjdxb3A0c2YxV2dKYlBUc2pzNVFyOVU4c255SW1JbVVDcENlV1pkTGxQNTR6clE?oc=5","date":"2018-02-15","type":"pipeline","source":"BioPharma Dive","summary":"Bioverativ taps new manufacturer as it steps out of Biogen’s shadow - BioPharma Dive","headline":"Bioverativ taps new manufacturer as it steps out of Biogen’s shadow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPeWVlR3ZTT1hnQWRFcUtaN3RqMUNxX0JzV3RjYlpGUVJTclhWcWhKN0prVXFPVlJMcG5CTVRsWWdUZ05CM3MyZzk1aGxJSVV5ZUI4bXFFWnJ0UjJ6bGV1TjVqZFpscWJwV1NqdlNLX1I5c0VRcmZTdHlqSFZxTnQ2U3lRM0xwU3VQSDlCRS1WcTUyaDd3VUE?oc=5","date":"2018-01-22","type":"deal","source":"Fierce Pharma","summary":"Sanofi snaps up Biogen's spun-out Bioverativ in $11.6B deal - Fierce Pharma","headline":"Sanofi snaps up Biogen's spun-out Bioverativ in $11.6B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQUjZxTjIzX3BMYzc1cGR0eU5SSUdJZnBubnFHZ3lyeEVHSHNzTjI3M3FvRHFPdkl5TjEzc2EzZFZQQkVqQ3lqSE9YX3Bac0thcDJiTF9meFZ1Njdwdm1fWnVKSmFDMElYbDFXQnVPdWo4N2lFa1B6YUNxX3Q1QmhCY0pPaFl5Ti1qTHVKNGtn?oc=5","date":"2018-01-22","type":"deal","source":"Pharmaceutical Technology","summary":"Sanofi acquires Bioverativ for $11.6bn - Pharmaceutical Technology","headline":"Sanofi acquires Bioverativ for $11.6bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOYWd2cGZnd2d1U3NxTGhDZDFGcy1OYk5jdHlJZlhUaHNLd1dEekVDai0xOXZLYy15UXlTdHIxd1NuTlZZbGpjRGhadkNLVnkwOVotV2VGbGJ6NnRVUDh3V0lOSl9Yb0hhY0hLNmJTblFMeUE5ZVNmWmlXMmpBLUdXdXFONlM?oc=5","date":"2018-01-22","type":"pipeline","source":"finance.yahoo.com","summary":"In Latest Lateral Payoff, Paul Weiss Grabs Role in Bioverativ Sale - finance.yahoo.com","headline":"In Latest Lateral Payoff, Paul Weiss Grabs Role in Bioverativ Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOb09VdkMyUUU4NkUwdE40Z2tPSGpwMG90OFE2VUFTaXVDWEdERjdESVVSdWhLdU5IczdxQ2V3ZElKREVycFVTM0ZwcGVMZ0pPVjEwalhLeFpDRzhyU1NLZVltbVdwRC10Zk05dnRxaFhUQktlN3JnR1NmdC1aVi10SER5d0hXaWIwNHVsRE40YUg5a1cyV1E?oc=5","date":"2018-01-22","type":"deal","source":"BioPharma Dive","summary":"Sanofi beefs up pipeline with $11B Bioverativ buy - BioPharma Dive","headline":"Sanofi beefs up pipeline with $11B Bioverativ buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNb25sY2RSeUNLd0h3ZmtYYS0zOURlcHhDdWEzaVVtbDVjZU5nQUEtQ0oxME1mYVpWYWNHOEhrZHlCLTQyUjNfMUNpSWRMcWVUTjhGTkp3UXhsNHcwX2twVFNYdkRCTnAtRW8zTDctLVByUnVlVERIOEI4RnI1TDU1N0loNWJ2UjVVN3FHZ3phOVRheFZ5aDBOcnFnMWw5TmdHQ18yX0xFaS1iaUQzX09IenZMMU53eDhORkpyR0JkTFljWWVQdXc?oc=5","date":"2016-08-09","type":"pipeline","source":"Biogen","summary":"Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company - Biogen","headline":"Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"marketed":4,"phase_3":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}